Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: Taiwan-Based Healthcare Fund Invests Up to $10M in Therapeutics & Medical Device Companies

13 Feb

A firm based in Taiwan is managing a healthcare fund that invests in several sectors within healthcare. The firm generally participates in Series A or B rounds and prefers a clear exit in less than 5 years. The firm is open to both leading and co-investing. Typical equity investments range from US$2-10M. The firm currently focuses 60% on Taiwan-based deals and 40% on China- and US-based deals.

The firm considers therapeutics and medical devices. Within therapeutics, the firm is open to all modalities including small molecules, biologics, cell therapy and gene therapy with a focus on cancer therapies. The firm would also consider R&D services, healthcare services, and healthcare IT products such as EMR management software. The firm seeks to invest in venture stage companies in Series A or B rounds.

The fund is looking for strong management teams with business background and a successful track record. The firm typically requests a board seat in their portfolio company. The firm collaborates with some of the top healthcare VC firms in Greater China and prefers companies that have a presence, or plan to establish one, in Taiwan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Venture Arm of Large Corporation Invests in Healthcare, Pharma Services, and More with Capacity to Invest Up to $20M

13 Feb

A venture arm of a large corporation is a stage-agnostic investor, and makes investments from Series B to growth stage. Investments are therefore varied in size relative to the type of investment; initial allocations are most often from $5-10 million with the possibility of follow-on investments up to $20 million. The firm is open to opportunities worldwide but has previously focused on investing in the USA, Canada and Europe.

The firm focuses on four areas of innovation in healthcare; pharma services, data and analytics, digital supply chain, consumer health, value based care.

The firm is focused on financial returns in addition to how the parent corporation can potentially contribute value to the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Large Japan Corporation Seeks Active Investment & Partnership Opportunities Within Healthcare

13 Feb

A holding company of a large Japanese corporation focuses on healthcare as one of their main areas of interest. The mission of their venture group and corporate venture capital arm is to foster innovation across the group by investing in and partnering with strategic startups. In principle, the corporate venture capital arm is open to global opportunities and is geography and stage agnostic, but has specific preferences depending on the technology sector.

Healthcare/Medical is one of the major focus areas of the firm. The corporate venture capital arm is interested therapeutics solutions such as solutions beyond the pill (digital therapeutics) and around the pill (delivery systems etc). Therapeutics areas of interest are CNS, Autoimmune diseases, metabolic diseases, regenerative medicine, Aging related solutions and Vaccines. The corporate venture capital arm is also interested in diagnostics solutions based on genomics, metagenomics, metabolomics, healthcare ICT (biosensors etc), and medical big data.  Furthermore, medical devices for wound care, bone cement and hospital related infection treatment is also is an area of interest and is open to all classes of medical devices including 510k and PMA.

This corporate venture arm has a close, collaborative relationship with their group’s other active healthcare businesses and can also present opportunities to the pharma branch, CRO, CDMO branches as appropriate.

The firm is a flexible investor and does not require companies to have a Japan-centric angle. For medical device & digital therapeutics opportunities, the group does prefer technologies with strong promise in the US market. The venture group has a close relationship with all other business operations within the corporation, and can actively support companies by leveraging these relationships. For example, the group can help with Japan market entry and clinical trials through their business arm that specializes in clinical trials, with established CRO, CDMO, ICT services.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Western Europe-Based Financial Institution Seeks Therapeutics & Device Investment Opportunities with Focus in France

13 Feb

A major financial institution based in Western Europe is focused on life sciences. The firm both invests in venture capital funds and makes direct investments in seed-stage and early-stage companies. Typically the firm invests EUR 0.5-3 million initially, with further capital reserved for follow-on rounds. The firm primarily invests in France, but will consider opportunities in other areas of Europe.

The firm is interested in opportunities in biotech and medical devices, and may potentially invest in digital health.  The firm is not interested in diagnostics. The firm has a broad interest in early stage therapeutics, including small molecules, biologics, cell and gene therapies, and all indication areas including cardiovascular, neurology, and rare diseases.  The firm is open to investing in repurposed drugs.  The firm invests from preclinical-stage companies through to Phase II.

The firm prefers to invest in companies based in France, but will consider opportunities elsewhere in Europe: within France the firm is typically a lead investor, but in other regions The firm prefers to be a follow-on investor. The firm focuses on investing in companies which have also received an investment from a VC that the firm is invested in.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Corporate Venture Arm of Large Company Invests Up to $6M in Therapeutics & Therapeutic Platforms with Strategic Fit

6 Feb

A corporate venture capital arm of a global company invests to further the parent company’s future strategic position, rather than purely for financial returns.  The firm looks to make equity investments into emerging biotech companies with typical investments ranging from $1 million to $6 million, with additional capital reserved for follow on investments. The firm has no set allocations it plans to make over the next year but is actively reviewing new opportunities. The firm considers opportunities located around the globe.

The firm is looking for biopharmaceutical companies developing therapeutics and therapeutic platforms generally at the preclinical stage and is open to considering both small molecules, biologics, nucleic acid, and gene and cellular therapeutic approaches. The firm is interested in various indications including immunology and autoimmune diseases (rheumatology, dermatology and gastroenterology), neuroscience (only neurodegenerative diseases) and oncology. The firm is not investing in diagnostics, devices or healthcare IT.

The firm is looking for companies with experienced management teams with domain expertise. The firm strongly prefers board representation following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA & China-Based VC Firm Highly Interested in Pre-Clinical to Phase II Novel Therapeutics, and Medical Devices

6 Feb

Founded in 2016, the firm has offices in USA and China. The firm has two RMB funds and one USD fund: The two RMB funds focus on the local Chinese market; while the USD fund invests in Hong Kong and non-China market. The firm’s USD Fund has invested in 7 companies, half of which are in the novel drugs area, and will continue to invest in Seed to pre-Series A. The typical allocation size will be $0.5MM to $1 MM, and up to $3.5 MM.

The firm is mainly interested in the Therapeutics innovations including orphan drugs, that are in pre-clinical to Phase II stage, especially CAR-T, small molecules and CRISPR. The firm is also open to medical devices companies, which are in development or clinical stage, but holds a strict valuation on diagnostics companies. The firm is not interested in Healthcare IT.

The firm has no specific company & management Team Requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Firm in Korea Seeks Therapeutics & Diagnostics Technologies in CNS, Oncology/Immuno-Oncology

6 Feb

A holding company based in South Korea is actively seeking global early-stage investment opportunities in bio/healthcare sectors, and actively invest in biotech VC funds as well. Initial size of investment largely depends on a deal-by-deal basis.

With regards to life sciences, the firm is most interested in therapeutics or diagnostics companies with a particular interest in platform technologies. The firm is most interested in CNS, oncology, and immuno-oncology opportunities. While the firm is open to investing in medical devices or digital health, these are not a priority for the firm.

The firm does not have specific company or management team requirements. The firm does not require companies to have a Korea angle or market potential in Korea, but the firm can provide strategic value add if the companies were interested in Asia market expansion.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: